A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country

• Published in: Journal of oncology pharmacy practice 2024-08, p.10781552241266254
• Main Authors: Abdullah, Abid, Areesha, Saeed, Humza, Zabeehullah, Iftikhar, Uswa, Arshad, Muhammad Khubaib, Shahid, Muhammad Uzair, Rasool, Tayyab, Fazal, Faizan, Goyal, Aman, Akbar, Anum
• Format: Article
• Language: English
• ISSN: 1078-1552; 1477-092X; 1477-092X
• DOI: 10.1177/10781552241266254

Breast cancer is one of the top three malignancies worldwide. While radiotherapy, hormone replacement therapys, and chemotherapy are treatments, chemotherapy causes adverse effects that hinder daily life activities. To assess the prevalence, severity, and association of symptomatic toxicities in female breast cancer patients affecting various organ systems post systemic chemotherapy (adjuvant and neoadjuvant), and their impact on daily activities. Additionally, to determine the severity of adverse effects in specific age groups and their association with family history and disease stage. An observational study was conducted on 253 female breast cancer patients receiving chemotherapy at NORI Cancer Hospital from May to October 2023. Data collection tools included the NCI-PRO-CTCAE standardized questionnaire and patient medical records. Analysis was performed using descriptive statistics, T-tests, and Chi-square tests. Among the 253 patients, 41.4% were aged 41-50. Significant weight changes ( = 0.034) were observed with more than three chemotherapy cycles. Notable associations included increased chemotherapy cycles with gastrointestinal (mouth/throat sores = 0.031, vomiting = 0.021), respiratory (cough = 0.04), cardiovascular (arm/leg swelling = 0.007, palpitations = 0.052), integumentary (hair loss = 0.000, skin dryness = 0.054), and musculoskeletal (fatigue = 0.002) adverse effects. Positive family history and the 18-30 age group also showed significant associations with adverse effect severity. Disease stage significantly influenced the nervous system (stage 2 = 0.007, stage 3 = 0.01). The severity of adverse effects varies among age groups, depending on disease stage, genetics, and treatment duration. These patient-reported outcomes highlight the need for better management strategies considering prognostic factors and treatment adverse effects.